ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,319.31
2.30%
US Tech 100
18,004.00
3.53%
Dow Jones
39,446.49
1.76%
Brent Oil
79.05
0.39%
Bitcoin
61,383.08
-0.57%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. G1 Therapeutics Inc (GTHX)

  7. G1 Therapeutics Inc (GTHX) News

GTHX

G1 Therapeutics (GTHX)

G1 Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GTHX
DateTimeSourceHeadlineSymbolCompany
08/08/20244:14PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GTHXG1 Therapeutics Inc
08/08/20244:01PMEdgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:GTHXG1 Therapeutics Inc
08/08/20246:54AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
08/08/20246:30AMGlobeNewswire Inc.G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
08/07/20245:30PMEdgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:GTHXG1 Therapeutics Inc
08/07/20245:10PMEdgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:GTHXG1 Therapeutics Inc
08/07/20245:03PMEdgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:GTHXG1 Therapeutics Inc
08/07/20249:21AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
08/07/20246:29AMGlobeNewswire Inc.Pharmacosmos Group to Acquire G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics Inc
08/01/20246:50PMGlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
07/25/202411:15AMGlobeNewswire Inc.G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024NASDAQ:GTHXG1 Therapeutics Inc
07/08/20245:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
07/08/20245:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
07/08/20245:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
07/08/20245:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
07/08/20245:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
07/01/20248:00AMGlobeNewswire Inc.G1 Therapeutics Added to the Russell 2000® and 3000® IndexesNASDAQ:GTHXG1 Therapeutics Inc
06/24/20246:30AMGlobeNewswire Inc.G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)NASDAQ:GTHXG1 Therapeutics Inc
06/14/20244:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
06/14/20244:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
06/14/20244:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
06/14/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
06/14/20244:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
06/14/20244:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
06/05/20247:00AMGlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
05/28/20246:30AMGlobeNewswire Inc.Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)NASDAQ:GTHXG1 Therapeutics Inc
05/24/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
05/23/20245:06PMGlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingNASDAQ:GTHXG1 Therapeutics Inc
05/22/202410:00AMGlobeNewswire Inc.G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitNASDAQ:GTHXG1 Therapeutics Inc
05/22/20246:30AMGlobeNewswire Inc.G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesNASDAQ:GTHXG1 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GTHX

Your Recent History

BIT
UC5F13
Unicredit Bank
TG
CQL
Dayforce
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved